The life sciences industry (pharmaceuticals, biotechnology and medical devices) faces significant risks inherent in their business. Executives and directors must address the continual demands of a multitude of constituents, including regulators, investors, partners, insurers, physicians, patients, lawyers and the media. Meeting these needs adds complexity and heightens risk, and as these risks converge and overlap, management of them becomes simultaneously more difficult and more essential.

This paper—the fourth title in the Risk Intelligence series—provides practical guidance and real-world examples of how to more effectively address the industry's complex risk matrix and cites a number of fundamental steps organizations need to undertake to create a Risk Intelligent Enterprise.™

Previous white papers in the Risk Intelligence series
 The risk intelligent enterprise: ERM for the energy Industry
 Risk intelligence in the age of global uncertainty
 The risk intelligent enterprise: ERM done right

Podcast: The risk intelligent enterprise—The rewards of risk